Hiroyuki Okuzawa
Profile
Performance in office
Tenure
Tenure
Background
He joined Sankyo in 1986. Sankyo and Daiichi Pharmaceutical created Daiichi Sankyo through a share transfer in September 2005, and Hiroyuki Okuzawa came up through Sankyo, one of the two predecessors. He became Executive Officer in April 2018, Managing Executive Officer and CFO in April 2021, Director in June 2021, and Director and Senior Executive Officer in April 2022, rising from the finance side to Representative Director, President and COO in April 2023. In April 2025 he became Representative Director, President and CEO.
Selection
In April 2023 Sunao Manabe moved to Chairman and CEO, and Hiroyuki Okuzawa took over as President. Manabe remained CEO; Okuzawa became President and CEO in April 2025. In the fiscal year before he took office, ended March 2023, consolidated revenue was ¥1,278.5 billion and operating income ¥120.6 billion, up from ¥1,044.9 billion in FY ended March 2022. Enhertu grew into the mainstay, earning about ¥450 billion in FY ended March 2024, roughly 30% of revenue of ¥1,601.7 billion. He was appointed after two years as Managing Executive Officer and CFO.
Initiatives
The number of DXd ADC candidates besides Enhertu grew to seven, one developed with AstraZeneca and three with U.S.-based Merck, under contracts that would pay up to ¥660 billion from AstraZeneca and up to ¥3.3 trillion from Merck if the drugs reach market. In over-the-counter drugs, the company decided to sell Daiichi Sankyo Healthcare to Suntory Holdings; the unit, which owns the painkiller Loxonin, ranked second in Japan and posted sales of about ¥76.0 billion with an operating margin of about 17% in FY ended March 2025. The sale price is about 3.6 times net assets, and the company will reduce its stake in stages.
Career
Career
Daiichi Sankyo
| Date | Position |
|---|---|
| Apr 1986 | Joined |
| Apr 2018 | Executive Officer |
| Apr 2021 | Managing Executive Officer, CFO |
| Jun 2021 | Director, Managing Executive Officer |
| Apr 2022 | Director, Senior Managing Executive Officer |
| Apr 2023 | Representative Director, President and COO |
| Apr 2025 | Representative Director, President and CEO |